Quick Answer
Foghorn Therapeutics Inc. reported Total Assets of $198.10 million for the year ending 2025.
- Foghorn Therapeutics Inc. showed a decrease of -30.2% in Total Assets from 2024 to 2025.
- This data is from Foghorn Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $142.43 million | Q1 2021: $229.89 million | Q2 2021: $208.53 million | Q3 2021: $186.07 million | Q1 2022: $488.31 million | Q2 2022: $456.90 million | Q3 2022: $433.93 million | Q1 2023: $372.88 million | Q2 2023: $339.58 million | Q3 2023: $313.42 million | Q1 2024: $255.00 million | Q2 2024: $328.59 million | Q3 2024: $308.37 million | Q1 2025: $258.69 million | Q2 2025: $226.24 million | Q3 2025: $204.96 million.
- Over the full 7 years of available data (2019 to 2025), Foghorn Therapeutics Inc.'s Total Assets has grown by 786.7%.
- Historical annual values: Fiscal year 2025: $198.10 million | Fiscal year 2024: $283.98 million | Fiscal year 2023: $285.92 million | Fiscal year 2022: $404.88 million | Fiscal year 2021: $519.77 million | Fiscal year 2020: $255.59 million | Fiscal year 2019: $22.34 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: